133 results about "Mouse Macrophage" patented technology

The invention relates to the field of a preparation method and application of a traditional Chinese medicine effective component and in particular relates to a preparation method of rhizoma polygonatipolysaccharide and application of the rhizoma polygonati polysaccharide to the preparation of an immunological enhancement medicine. The rhizoma polygonati polysaccharide is obtained by processing raw rhizoma polygonati, extracting and separating; when an extraction method provided by the invention is adopted, the extraction rate of the rhizoma polygonati polysaccharide is high and the content oftotal polysaccharide is high; the proliferation activity of the rhizoma polygonati polysaccharide on normal mouse spleen cells is improved; cyclophosphamide induced spleen and thymus gland index of mice with low immunity also can be improved; the in-vitro proliferation capability of spleen and thymus gland cells under the stimulation of concanavalin A is enhanced; the phagocytic function of macrophage of the mice with the low immunity and the capability of secreting IL-6 and TNF-alpha are enhanced; the rhizoma polygonati polysaccharide has actual application value in the aspect of treatment of diseases including immunodeficiency diseases, tumors and the like.

The invention discloses a method for capturing high-purity circulating tumor cells based on a biological orthogonal chemical method. The method comprises the following steps: s1, preparing superparamagnetic ferroferric oxide nanoparticles; s2, preparing a bionic magnetic vesicle; s3, performing functional modification on the bionic magnetic vesicles; s4, growing azide genes on the surfaces of thetumor cells; and s5, capturing the circulating tumor cells. After superparamagnetic ferroferric oxide nanoparticles and macrophages are incubated, bionic magnetic vesicles can be generated through mouse macrophages in a way similar to exosome release, and then functional modification is carried out; tumor cells generate functional groups on the surfaces of cell membranes in advance through intracellular metabolism of the tumor cells, the tumor cells are incubated with the functionalized magnetic vesicles, the two functional groups are combined through bioorthogonal chemistry, capture of circulating tumor cells is achieved, and the mode has the potential of being applied to liquid biopsy.

The invention discloses a gene associated with the toxicity of Brucella and application of the gene in evaluation of the toxicity of the Brucella and preparation of low-toxicity Brucella. By using a homologous recombination method, a ribosome gene L31 of the Brucella M28 is replaced by a kanamycin gene, and a Brucella L31 gene deletion strain M28deltaL31 is obtained. By using macrophages RAW264.7and a Babl / c mouse model, the influence of the Brucella L31 gene on the toxicity of the Brucella M28 is evaluated. Through results, it is shown that after the L31 gene is deleted, the growth of the M28 cannot be affected, but the duplication survival capacity of the high-toxicity strain M28 in the mouse macrophage system RAW264.7 and the mouse spleen can be obviously reduced, after the L31 gene issupplemented in the M28deltaL31, the toxicity can recover to the level of a wild strain, and it is proved that the gene is associated with the toxicity of the Brucella M28. The gene for predicting the toxicity can be used for research and development of new brucella vaccines, and the gene has a potential application value.

The invention provides application of myricanol and / or myricetin to preparation of a medicine for preventing and / or treating inflammatory bowel diseases. The inflammatory bowel diseases are treated through the myricanol and / or the myricetin. The myricanol and / or the myricetin have / has an inhibition effect on IL-6, TNF-alpha and IL-1beta inflammatory factors secreted by RAW264.7 cells of mouse macrophage in vitro, and inhibition on expression of inflammatory factors is generated; more particularly, the myricanol and / or the myricetin have / has an inhibition effect on the inflammatory bowel diseases and have no obvious toxic and side effects in a medicinal effect expressing process; the ulcer area is effectively reduced. Compared with existing aminosalicylic acid medicines, the myricanol and / or the myricetin have / has a better curative effect and are / is suitable for large-scale production; the myricanol and / or the myricetin have / has a wide application prospect and relatively high application value.

The invention discloses dendrobium officinale leaf fermented wine which is prepared from fresh dendrobium officinale leaves, olive fruits, white granulated sugar, bacteria powder and distilled water according to certain weight part proportions, wherein the bacteria powder is prepared by mixing lactobacillus plantarum, rhamnose bacteria, lactic acid bacteria DU-106, saccharomycetes, NaCl, glucose,inulin and dietary fiber according to proportions. The preparation method of the dendrobium officinale leaf fermented wine comprises the following steps: raw material selection; blanching with boiledwater; preparation of alcohol liquid; diastatic fermentation; aging fermentation; clarification and degerming; distillation of the alcohol liquid to obtain the dendrobium officinale leaf fermented wine. The dendrobium officinale leaf fermented wine has mellow wine flavor. Tastes smooth and mellow, and has sour-sweet and tasty taste; the wine is light pink, clarified, stable and uniform. The dendrobium officinale leaf fermented wine has nutritional effects of the fresh dendrobium officinale leaves, and also has physiological and health-care effects achieved by fermentation and metabolism of lactic acid-production bacillus and saccharomyces cerevisiae. The alcohol content is 6 to 15 percent, the total acid content is 0.5 to 1.5 percent, and the polysaccharide content is 0.5 to 0.8 percent. The dendrobium officinale leaf fermented wine has an outstanding immunobiological activity; the phagocytosis activity of RAW 264.7 mice macrophage and the secretion volume of relevant immunocytokines can be improved.

The invention relates to application of a novel phenolic acid compound in preparation of an anti-inflammatory drug, and also relates to a preparation method for extracting, separating and purifying the compound from a traditional Chinese medicine sabia parviflora. Pharmacological research shows that the novel compound can remarkably inhibit the levels of NO, IL-1, IL-6 and TNF-alpha in mouse macrophages RAW246.7 caused by lipopolysaccharide (LPS), and the inhibition effect is mostly dependent on a dose, so the compound has obvious anti-inflammatory activity and can be used for preparing anti-inflammatory drugs. The preparation method is simple and easy to implement, and the obtained compound is high in purity and has good economic benefits and application prospects.

The invention relates to an application of sulfated chlorella and spirulina composite polysaccharides in the immunoloregulation field. The sulfated composite polysaccharides have immunoloregulation activity, can enhance the neutral red phagocytosis ability of macrophages in mice, can improve the NO production ability of the macrophages and significantly improve the proliferation of splenic lymphocytes in the mice, and can improve the DNFB induced delayed allergy of the mice to enhance the immunity of the mice.

The invention discloses an iridoid glycoside compound, which is a novel chemical component discovered from cape jasmines. The compound separated by virtue of the method is further structurally identified by virtue of measures of physicochemical properties and modern spectroscopy. Activity evaluation is further carried out by virtue of activity screening systems such as an LPS-induced RAW 264.7 cell inflammation model so as to discover that the compound has a certain protecting effect on a mouse macrophage system RAW 264.7, is capable of remarkably inhibiting PGE2 and presents a relatively strong anti-inflammatory action.

The invention provides application of myricanol and / or myricetin to preparation of a medicine for preventing and / or treating inflammatory bowel diseases. The inflammatory bowel diseases are treated through the myricanol and / or the myricetin. The myricanol and / or the myricetin have / has an inhibition effect on IL-6, TNF-alpha and IL-1beta inflammatory factors secreted by RAW264.7 cells of mouse macrophage in vitro, and inhibition on expression of inflammatory factors is generated; more particularly, the myricanol and / or the myricetin have / has an inhibition effect on the inflammatory bowel diseases and have no obvious toxic and side effects in a medicinal effect expressing process; the ulcer area is effectively reduced. Compared with existing aminosalicylic acid medicines, the myricanol and / or the myricetin have / has a better curative effect and are / is suitable for large-scale production; the myricanol and / or the myricetin have / has a wide application prospect and relatively high application value.